Generic Ozempic Could Cost Less Than $3 a Month, Study Shows

March 6, 2026, 8:30 AM UTC

Generic versions of Novo Nordisk A/S’s hit shots Ozempic and Wegovy could be sold for under $3 a month, a new study showed, underscoring their potential to unlock global access to powerful weight-loss drugs.

Generic injectable semaglutide, the main ingredient in both blockbuster drugs, could cost $28 to $140 a year, according to researchers at the University of Liverpool. By contrast, Novo’s US list price is $1,027.51 for Ozempic and $1,349 for Wegovy, though it has pledged to cut both to $675 on Jan. 1. Direct-to-consumer prices are lower, at $349 a month for most doses of Wegovy. ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.